The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 81, Issue , 2018, Pages 55-63

  Réus, Gislaine Z ^a   Becker, Indianara R T ^a   Scaini, Giselli ^b   Petronilho, Fabricia ^a   Oses, Jean P ^c   Kaddurah Daouk, Rima ^d,f   Ceretta, Luciane B ^e   Zugno, Alexandra I ^a   Dal Pizzol, Felipe ^a   Quevedo, João ^a,b,e   Barichello, Tatiana ^a,b  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Animal model; Ketamine; Kynurenine pathway; Oxidative stress; Schizophrenia

Indexed keywords

ALLOPURINOL; INDOLEAMINE 2,3 DIOXYGENASE; KETAMINE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; MESSENGER RNA; SUPEROXIDE DISMUTASE; TRYPTOPHAN 2,3 DIOXYGENASE; ENZYME INHIBITOR; NEUROLEPTIC AGENT;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME INHIBITION; HIPPOCAMPUS; LIPID PEROXIDATION; LOCOMOTION; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SCHIZOPHRENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DISEASE MODEL; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KETAMINE; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; MALE; MOTOR ACTIVITY; OXIDATIVE STRESS; RATS, WISTAR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRYPTOPHAN OXYGENASE;

EID: 85031723635     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2017.10.009     Document Type: Article

References (79)

1. Anderson, G., Maes, M., Schizophrenia: linking prenatal infec- tion to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 42 (2013), 5–19.
2. Blanco Ayala, T., Lugo, Huitrón R., Carmona Aparicio, L., Ramírez Ortega, D., González Esquivel, D., Pedraza Chaverrí J., Pérez de la Cruz, G., Ríos, C., Schwarcz, R., Pérez de la Cruz, V., Alternative kynurenic acid synthesis routes studied in the rat cerebellum. Front. Cell. Neurosci., 9, 2015, 178.
3. Breton, J., Avanzi, N., Magagnin, S., Covini, N., Magistrelli, G., Cozzi, L., Isacchi, A., Functional characterization and mechanism of action of recombinant human kynurenine 3-hydroxylase. Eur. J. Biochem. 267 (2000), 1092–1099.
4. Bryleva, E.Y., Brundin, L., Kynurenine pathway metabolites and suicidality. Neuropharmacology 112 (2017), 324–330.
5. Canever, L., Oliveira, L., D'Altoe de Luca, R., Correa, P.T., de BFD, Matos M.P., Scaini, G., Quevedo, J., Streck, E.L., Zugno, A.I., A rodent model of schizophrenia reveals increase in creatine kinase activity with associated behavior changes. Oxidative Med. Cell. Longev. 3:6 (2010), 421–427.
6. Cervenka, I., Agudelo, L.Z., Ruas, J.L., Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health. Science, 357(6349), 2017.
7. Damazio, L.S., Silveira, F.R., Canever, L., Castro, A.A., Estrela, J.M., Budni, J., Zugno, A.I., The preventive effects of ascorbic acid supplementation on locomotor and acetylcholinesterase activity in an animal model of schizophrenia induced by ketamine. An. Acad. Bras. Cienc. 89 (2017), 1133–1141.
8. Dang, Y., Dale, W.E., Brown, O.R., Effects of oxygen on kynurenine-3-monooxygenase activity. Redox Rep. 5 (2000), 81–84.
9. Dauvermann, M.R., Lee, G., Dawson, N., Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. Br. J. Pharmacol. 174 (2017), 3136–3160.
10. Dringen, R., Oxidative and antioxidative potential of brain microglial cells. Antioxid. Redox Signal. 7 (2005), 1223–1233.
11. Erhardt, S., Pocivavsek, A., Repici, M., Liu, X.C., Imbeault, S., Maddison, D.C., Thomas, M.A., Smalley, J.L., Larsson, M.K., Muchowski, P.J., Giorgini, F., Schwarcz, R., Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders. Biol. Psychiatry, 2016, 10.1016/j.biopsych.2016.12.011 (pii: S0006-3223(16)33112-2).
12. Fraga, D.B., Réus, G.Z., Abelaira, H.M., De Luca, R.D., Canever, L., Pfaffenseller, B., Colpo, G.D., Kapczinski, F., Quevedo, J., Zugno, A.I., Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration. Rev. Bras. Psiquiatr. 35 (2013), 262–266.
13. Fraguas, D., Díaz-Caneja, C.M., Rodríguez-Quiroga, A., Arango, C., Oxidative stress and inflammation in early onset first episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 20 (2017), 435–444.
14. Frohlich, J., Van Horn, J.D., Reviewing the ketamine model for schizophrenia. J. Psychopharmacol. 28 (2014), 287–302.
15. Ghedim, F.V., Fraga, D.B., Deroza, P.F., Oliveira, M.B., Valvassori, S.S., Steckert, A.V., Budni, J., Dal-Pizzol, F., Quevedo, J., Zugno, A.I., Evaluation of behavioral and neurochemical changes induced by ketamine in rats: implications as an animal model of mania. J. Psychiatr. Res. 46 (2012), 1569–1575.
16. Gibney, S.M., Fagan, E.M., Waldron, A.M., O'Byrne, J., Connor, T.J., Harkin, A., Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int. J. Neuropsychopharmacol. 29 (2014), 1–12.
17. Golimbet, V.E., Korovaĭtseva, G.I., Gabaeva, M.V., Velikaia, N.V., Snegireva, A.A., Kasparov, S.V., Kolesina, NIu., Ganisheva, T.K., Savel'eva, T.M., A study of IL-1Β and IDO gene polymorphisms in patients with schizophrenia. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova. 114 (2014), 46–49.
18. González Esquivel, D., Ramírez-Ortega, D., Pineda, B., Castro, N., Ríos, C., Pérez de la Cruz, V., Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology 112 (2017), 331–345.
19. Gonzalez-Liencres, C., Tas, C., Brown, E.C., Erdin, S., Onur, E., Cubukcoglu, Z., Aydemir, O., Esen-Danaci, A., Brüne, M., Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition. BMC Psychiatry, 14, 2014, 268.
20. Guillemin, G.J., Kerr, S.J., Smythe, G.A., Kapoor, V., Armati, P.J., Croitoru, J., Brew, B.J., Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78 (2001), 842–853.
21. Haber, R., Bessette, D., Hulihan-Giblin, B., Durcan, M.J., Goldman, D., Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J. Neurochem. 60 (1993), 1159–1162.
22. Hardingham, G.E., Do, K.Q., Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat. Rev. Neurosci. 17 (2016), 125–134.
23. Hilmas, C., Pereira, E.F., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, E.X., The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21 (2001), 7463–7473.
24. Holtze, M., Saetre, P., Erhardt, S., Schwieler, L., Werge, T., Hansen, T., Nielsen, J., Djurovic, S., Melle, I., Andreassen, O.A., Hall, H., Terenius, L., Agartz, I., Engberg, G., Jönsson, E.G., Schalling, M., Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: an association study. Schizophr. Res. 127 (2011), 270–272.
25. Jhamandas, K.H., Boegman, R.J., Beninger, R.J., Miranda, A.F., Lipic, K.A., Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox. Res. 2 (2000), 139–155.
26. Jia, L., Schweikart, K., Tomaszewski, J., Page, J.G., Noker, P.E., Buhrow, S.A., Reid, J.M., Ames, M.M., Munn, D.H., Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem. Toxicol. 46 (2008), 203–211.
27. Johansson, A.S., Owe-Larsson, B., Asp, L., Kocki, T., Adler, M., Hetta, J., Gardner, R., Lundkvist, G.B., Urbanska, E.M., Karlsson, H., J. Psychiatr. Res. 47 (2013), 1815–1823.
28. Kanchanatawan, B., Sirivichayakul, S., Ruxrungtham, K., Carvalho, A.F., Geffard, M., Anderson, G., Maes, M., Deficit schizophrenia is characterized by defects in Igm mediated responses to TryptophanCatabolites (TRYCATs): a paradigm shift towards defects in natural self-regulatory ImmuneResponses coupled with mucosa-derived TRYCAT pathway activation. Mol. Neurobiol., 2017, 10.1007/s12035-017-0417-6.
29. Kanchanatawan, B., Sirivichayakul, S., Ruxrungtham, K., Carvalho, A.F., Geffard, M., Ormstad, H., Anderson, G., Maes, M., Deficit, but not nondeficit, schizophrenia is characterized by mucosa- associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic and quinolinic acid. Mol. Neurobiol., 2017, 10.1007/s12035-017-0465-y.
30. Karlsgodt, K.H., Robleto, K., Trantham-Davidson, H., Jairl, C., Cannon, T.D., Lavin, A., Jentsch, J.D., Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol. Psychiatry 69 (2011), 28–34.
31. Kegel, M.E., Bhat, M., Skogh, E., Samuelsson, M., Lundberg, K., Dahl, M.L., Sellgren, C., Schwieler, L., Engberg, G., Schuppe-Koistinen, I., Erhardt, S., Imbalanced kynurenine pathway in schizophrenia. Int. J. Tryptophan. Res. 7 (2014), 15–22.
32. Kessler, M., Terramani, T., Lynch, G., Baudry, M., A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J. Neurochem. 52 (1989), 1319–1328.
33. Konradsson-Geuken, A., Wu, H.Q., Gash, C.R., Alexander, K.S., Campbell, A., Sozeri, Y., Pellicciari, R., Schwarcz, R., Bruno, J.P., Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience 169 (2010), 1848–1859.
34. Koola, M.M., Buchanan, R.W., Pillai, A., Aitchison, K.J., Weinberger, D.R., Aaronson, S.T., Dickerson, F.B., Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophr. Res. 157 (2014), 84–89.
35. Larson, M.K., Walker, E.F., Compton, M.T., Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev. Neurother. 10 (2010), 1347–1359.
36. Leklem, J.E., Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am. J. Clin. Nutr., 24, 1971, 659e72.
37. Leonard, B., Maes, M., Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 36 (2012), 764–785.
38. Lin, H., Hsu, F.C., Baumann, B.H., Coulter, D.A., Lynch, D.R., Cortical synaptic NMDA receptor deficits in alpha7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases. Neurobiol. Dis. 63 (2014), 129–140.
39. Little, J.L., Smith, L.H., Pulmonary aspiration. West. J. Med. 131:2 (1979), 122–129.
40. Lopresti, A.L., Maker, G.L., Hood, S.D., Drummond, P.D., A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress bio-markers. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 48, 2014, 102e11.
41. Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí J., Silva-Adaya, D., Maldonado, P.D., Torres, I., Pinzón, E., Ortiz-Islas, E., López, T., García, E., Pineda, B., Torres-Ramos, M., Santamaría, A., La Cruz, V.P., On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol. Teratol. 33 (2011), 538–547.
42. Maekawa, M., Watanabe, A., Iwayama, Y., Kimura, T., Hamazaki, K., Balan, S., Ohba, H., Hisano, Y., Nozaki, Y., Ohnishi, T., Toyoshima, M., Shimamoto, C., Iwamoto, K., Bundo, M., Osumi, N., Takahashi, E., Takashima, A., Yoshikawa, T., Polyunsaturated fatty acid deficiency during neurodevelopment in mice models the prodromal state of schizophrenia through epigenetic changes in nuclear receptor genes. Transl. Psychiatry, 7, 2017, e1229.
43. Medina-Hernández, V., Ramos-Loyo, J., Luquin, S., Sánchez, L.F., García-Estrada, J., Navarro-Ruiz, A., Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. J. Psychiatr. Res. 41 (2007), 652–658.
44. Miller, C.L., Llenos, I.C., Dulay, J.R., Barillo, M.M., Yolken, R.H., Weis, S., Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 15 (2004), 618–629.
45. Morris, G., Berk, M., Carvalho, A., Caso, J.R., Sanz, Y., Walder, K., Maes, M., The role of the microbial metabolites including trypto- phan catabolites and short chain fatty acids in the pathophysiology of immune-inflammatory and neuroimmune disease. Mol. Neurobiol. 54 (2017), 4432–4451.
46. Moylan, S., Berk, M., Dean, O.M., Samuni, Y., Williams, L.J., O'Neil, A., Hayley, A.C., Pasco, J.A., Anderson, G., Jacka, F.N., Maes, M., Oxidative & nitrosative stress in depression: why so much stress?. Neurosci. Biobehav. Rev. 45 (2014), 46–62.
47. Müller, N., Weidinger, E., Leitner, B., Schwarz, M.J., The role of inflammation in schizophrenia. Front. Neurosci., 9, 2015, 372.
48. Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., Belforte, J.E., GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 62 (2012), 1574–1583.
49. Nilsson, L.K., Linderholm, K.R., Engberg, G., Paulson, L., Blennow, K., Lindström, L.H., Nordin, C., Karanti, A., Persson, P., Erhardt, S., Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 80 (2005), 315–322.
50. O'Farrell, K., Fagan, E., Connor, T.J., Harkin, A., Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons. Eur. J. Pharmacol. 5:810 (2017), 163–173.
51. Okusaga, O.O., Accelerated aging in schizophrenia patients: the potential role of oxidative stress. Aging Dis. 5 (2013), 256–262.
52. Onaolapo, A.Y., Aina, O.A., Onaolapo, O.J., Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia. Biomed Pharmacother 92 (2017), 373–383.
53. Parasram, K., Phytochemical treatments target kynurenine pathway induced oxidative stress. Redox Rep., 2017, 1–4, 10.1080/13510002.2017.1343223.
54. Parrott, J.M., O'Connor, J.C., Kynurenine 3-monooxygenase: an influential mediator of neuropathology. Front. Psychiatry, 6, 2015, 116.
55. Paxinos, G., Watson, C., The Rat Brain: Stereotaxic Coordinates. second ed., 1986 (Australia).
56. Perkins, M.N., Stone, T.W., An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247 (1982), 184–187.
57. Plitman, E., Nakajima, S., de la Fuente-Sandoval, C., Gerretsen, P., Chakravarty, M.M., Kobylianskii, J., Chung, J.K., Caravaggio, F., Iwata, Y., Remington, G., Graff-Guerrero, A., Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur. Neuropsychopharmacol. 24 (2014), 1591–1605.
58. Plitman, E., Iwata, Y., Caravaggio, F., Nakajima, S., Chung, J.K., Gerretsen, P., Kim, J., Takeuchi, H., Chakravarty, M.M., Remington, G., Graff-Guerrero, A., Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr. Bull., 2017 (in press).
59. Réus, G.Z., Jansen, K., Titus, S., Carvalho, A.F., Gabbay, V., Quevedo, J., Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies. J. Psychiatr. Res. 68 (2015), 316–328.
60. Réus, G.Z., Fries, G.R., Stertz, L., Badawy, M., Passos, I.C., Barichello, T., Kapczinski, F., Quevedo, J., The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300 (2015), 141–154.
61. Réus, G.Z., Simões, L.R., Colpo, G.D., Scaini, G., Oses, J.P., Generoso, J.S., Prossin, A.R., Kaddurah-Daouk, R., Quevedo, J., Barichello, T., Ketamine potentiates oxidative stress and influences behavior and inflammation in response to lipolysaccharide (LPS) exposure in early life. Neuroscience 353 (2017), 17–25.
62. 1 receptor agonists. Psychopharmacology 210 (2010), 407–418.
63. Sathyasaikumar, K.V., Stachowski, E.K., Wonodi, I., Roberts, R.C., Rassoulpour, A., McMahon, R.P., Schwarcz, R., Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37 (2011), 1147–1156.
64. Schwarcz, R., Rassoulpour, A., Wu, H.Q., Medoff, D., Tamminga, C.A., Roberts, R.C., Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50 (2001), 521–530.
65. da Silva Araújo, T., Maia Chaves Filho, A.J., Monte, A.S., Isabelle de Góis Queiroz, A., Cordeiro, R.C., de Jesus Souza Machado, M., de Freitas Lima, R., Freitas de Lucena, D., Maes, M., Macêdo, D., Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. J. Psychiatr. Res. 84 (2017), 49–58.
66. Sone, J.M., Morrison, P.D., Pilowsky, L.S., Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J. Psychopharmacol. 21 (2007), 440–452.
67. Szymona, K., Zdzisińska, B., Karakuła-Juchnowicz, H., Kocki, T., Kandefer-Szerszeń M., Flis, M., Rosa, W., Urbańska, E.M., Correlations of kynurenic acid, 3-hydroxykynurenine, sIL-2R, IFN-α and IL-4 with clinical symptoms during acute relapse of schizophrenia. Neurotox. Res. 32 (2017), 17–26.
68. Tani, M., Akashi, N., Hori, K., Konishi, K., Kitajima, Y., Tomioka, H., Inamoto, A., Hirata, A., Tomita, A., Koganemaru, T., Takahashi, A., Hachisu, M., Anticholinergic activity and schizophrenia. Neurodegener. Dis. 15 (2015), 168–174.
69. Urenjak, J., Obrenovitch, T.P., Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum. J. Neurochem. 75 (2000), 2427–2433.
70. Wang, X., Pinto-Duarte, A., Sejnowski, T.J., Behrens, M.M., How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia. Antioxid. Redox Signal. 18 (2013), 1444–1462.
71. Wang, S.M., Han, C., Lee, S.J., Jun, T.Y., Patkar, A.A., Masand, P.S., Pae, C.U., Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opin. Investig. Drugs 26 (2017), 687–698.
72. Williams, M., Zhang, Z., Nance, E., Drewes, J.L., Lesniak, W.G., Singh, S., Chugani, D.C., Rangaramanujam, K., Graham, D.R., Kannan, S., Maternal inflammation results in altered tryptophan metabolism in rabbit placenta and fetal brain. Dev. Neurosci. 39 (2017), 399–412.
73. Wonodi, I., Stine, O.C., Sathyasaikumar, K.V., Roberts, R.C., Mitchell, B.D., Hong, L.E., Kajii, Y., Thaker, G.K., Schwarcz, R., Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 68 (2011), 665–674.
74. Wonodi, I., McMahon, R.P., Krishna, N., Mitchell, B.D., Liu, J., Glassman, M., Hong, L.E., Gold, J.M., Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia. Schizophr. Res. 160 (2014), 80–87.
75. Wurfel, B.E., Drevets, W.C., Bliss, S.A., McMillin, J.R., Suzuki, H., Ford, B.N., Morris, H.M., Teague, T.K., Dantzer, R., Savitz, J.B., Serum kynurenic acid is reduced in affective psychosis. Transl. Psychiatry, 7, 2017, e1115.
76. Xu, K., Lipsky, R.H., Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans. Exp. Biol. Med. 240 (2015), 145–155.
77. Zhang, X.Y., Chen, D.C., Xiu, M.H., Tang, W., Zhang, F., Liu, L., Chen, Y., Liu, J., Yao, J.K., Kosten, T.A., Kosten, T.R., Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr. Res. 139 (2012), 66–72.
78. Zugno, A.I., Chipindo, H.L., Volpato, A.M., Budni, J., Steckert, A.V., de Oliveira, M.B., Heylmann, A.S., Rosa, da, Silveira, F., Mastella, G.A., Maravai, S.G., Wessler, P.G., Binatti, A.R., Panizzutti, B., Schuck, P.F., Quevedo, J., Gama, C.S., Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience 259 (2014), 223–231.
79. Zugno, A.I., Canever, L., Heylmann, A.S., Wessler, P.G., Steckert, A., Mastella, G.A., de Oliveira, M.B., Damázio, L.S., Pacheco, F.D., Calixto, O.P., Pereira, F.P., Macan, T.P., Pedro, T.H., Schuck, P.F., Quevedo, J., Budni, J., Effect of folic acid on oxidative stress and behavioral changes in the animal model of schizophrenia induced by ketamine. J. Psychiatr. Res. 81 (2016), 23–35.